Depression, Anxiety, and Quality of Life in Patients Treated with Single Infusion Tocilizumab for COVID-19: A Follow-up, Controlled Study.
Rahul ChakravartySushmita GhoshalSamita PaulRitin MohindraManoj GoyalVikas SuriAshish BhallaShubh Mohan SinghPublished in: Indian journal of psychological medicine (2022)
Depressive and anxiety symptoms and impairment in QOL were reported more frequently and with greater severity in patients in the tocilizumab group at three months but not at six months. Psychological morbidity and impairment in QOL were modest and improved from 3 to 6 months.
Keyphrases
- sleep quality
- rheumatoid arthritis
- end stage renal disease
- coronavirus disease
- ejection fraction
- newly diagnosed
- juvenile idiopathic arthritis
- depressive symptoms
- rheumatoid arthritis patients
- chronic kidney disease
- prognostic factors
- bipolar disorder
- physical activity
- patient reported outcomes
- systemic lupus erythematosus
- disease activity
- respiratory syndrome coronavirus